Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis

BMC Veterinary Research

Volumn 10, Issue , 2014, Pages

  Permuy, María ^a   Guede, David ^b,c   López Peña, Mónica ^a   Muñoz, Fernando ^a   González Cantalapiedra, Antonio ^a   Caeiro, Jose Ramón ^c,d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Trabeculae SL   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Bisphosphonate; Bone; Cartilage; Glucosamine sulfate; Osteoarthritis; Risedronate; Synovial membrane

Indexed keywords

BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; GLUCOSAMINE; RISEDRONIC ACID;

ANALOGS AND DERIVATIVES; ANIMAL; FEMALE; HUMAN; OSTEOARTHRITIS; RABBIT; VETERINARY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; RABBITS; RISEDRONATE SODIUM;

EID: 84900809898     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-10-97     Document Type: Article

References (54)

1. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gosset C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256. 10.1016/S0140-6736(00)03610-2, 11214126.
2. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123. 10.1001/archinte.162.18.2113, 12374520.
3. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, Paulino J, Marenco JL, Porto A, Laffon A, Araújo D, Figueroa M, Branco J. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007, 56:555-567. 10.1002/art.22371, 17265490.
4. Shikhman AR, Amiel D, D'Lima D, Hwang SB, Hu C, Xu A, Hashimoto S, Kobayashi K, Sasho T, Lotz MMK. Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis 2005, 64:89-94. 10.1136/ard.2003.019406, 1755188, 15608304.
5. Tiraloche G, Girard C, Chouinard L, Sampalis J, Moquin L, Ionescu M, Reiner A, Poole AR, Laverty S. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum 2005, 52:1118-1128. 10.1002/art.20951, 15818693.
6. Da Camara CC, Dowless GV. Glucosamine sulfate for osteoarthritis. Ann Pharmacother 1998, 32:580-587. 10.1345/aph.17214, 9606480.
7. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, CD2:OC2946.
8. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 2001, 28:461-464. 10.1016/S8756-3282(01)00431-8, 11344044.
9. Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2002, 61:530-533. 10.1136/ard.61.6.530, 1754128, 12006327.
10. Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999, 878:453-465. 10.1111/j.1749-6632.1999.tb07702.x, 10415748.
11. Varghese S. Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front Biosci 2006, 11:2949-2966. 10.2741/2024, 16720367.
12. Pasternak B, Aspenberg P. Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop 2009, 80:693-703. 10.3109/17453670903448257, 2823312, 19968600.
13. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs 2004, 18:269-278. 10.2165/00063030-200418040-00004, 15244502.
14. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007, 74:32-38. 10.1016/j.jbspin.2006.06.005, 17196868.
15. Fujita T, Ohue M, Fujii Y, Mayauchi A, Takagi Y. Analgesic and chondroprotective effects of risedronate in osteoarthrosis assessed by electroalgometry and measurement of collagen type II fragments in urine. J Int Med Res 2008, 36:932-941. 10.1177/147323000803600509, 18831886.
16. Jones MD, Tran CW, Li G, Maksymowych WP, Zernicke RF, Doschak MR. In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum 2010, 62:2726-2735. 10.1002/art.27595, 20533290.
17. Doschak MR, LaMothe JM, Cooper DM, Hallgrimsson B, Hanley DA, Bray RC, Zernicke RF. Bisphosphonates reduce bone mineral loss at ligament entheses after joint injury. Osteoarthritis Cartilage 2005, 13:790-797. 10.1016/j.joca.2005.04.015, 16153550.
18. Doschak MR, Wohl GR, Hanley DA, Bray RC, Zernicke RF. Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. J Orthop Res 2004, 22:942-948. 10.1016/j.orthres.2003.12.018, 15304263.
19. Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003, 15:413-418. 10.1007/BF03327362, 14703007.
20. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: Results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633. 10.1186/ar1716, 1174954, 15899049.
21. Bingham CO, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507. 10.1002/art.22160, 17075851.
22. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. PLoS Biol 2010, 8(6):e1000412. doi:10.1371/journal.pbio.1000412, 10.1371/journal.pbio.1000412, 2893951, 20613859.
23. Donath K. The diagnostic value of the new method for the study of undecalcified bones and teeth with attached soft tissue (Säge-Schliff (sawing and grinding) technique). Pathol Res Pract 1985, 179:631-633. 10.1016/S0344-0338(85)80209-0, 3895202.
24. Laczkó J, Lévai G. A simple differential staining method for semi-thin sections of ossifying cartilage and bone tissues embedded in epoxy resin. Mikroskopie 1975, 31:1-4.
25. Pastoureau PC, Hunkizer EB, Pelletier JP. Cartilage, bone and synovial histomorphometry in animal models of osteoarthritis. Osteoarthritis Cartilage 2010, 18:S106-S112.
26. Cook JL, Kuroki K, Visco D, Pelletier JP, Shulz L, Lafeber FP. The OARSI histopathology initiative- recommendations for histological assessments of osteoarthritis in the dog. Osteoarthritis Cartilage 2010, 18:S66-S79.
27. Laverty S, Girard CA, Williams JM, Hunziker EB, Pritzek KPH. The OARSI histopathology initiative- recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthritis Cartilage 2010, 18:S53-S65.
28. Feldkamp LA, Davis LC, Kress JW. Practical cone-beam algorithm. J Opt Soc Am A 1984, 1:612-619.
29. Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999, 14:1167-1174. 10.1359/jbmr.1999.14.7.1167, 10404017.
30. Pritzker KP. Animal models for osteoarthritis: processes, problems and prospects. Ann Rheum Dis 1994, 53:406-420. 10.1136/ard.53.6.406, 1005358, 8037500.
31. Bendele AM. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact 2001, 1:363-376.
32. Shirai T, Kobayashi M, Nishitani K, Satake T, Kuroki H, Nakagawa Y, Nakamura T. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 2011, 29:1572-1577. 10.1002/jor.21394, 21462250.
33. Wang SX, Laverty S, Dumitriu M, Plaas A, Grynpas MD. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum 2007, 56:1537-1548. 10.1002/art.22574, 17469133.
34. Sah RL, Yang AS, Chen AC, Hant JJ, Halili RB, Yoshioka M, Amiel D, Coutts RD. Physical properties of rabbit articular cartilage after transection of the anterior cruciate ligament. J Orthop Res 1997, 15:197-203. 10.1002/jor.1100150207, 9167621.
35. Calvo E, Palacios I, Delgado E, Sánchez-Pernaute O, Largo R, Egido J, Herrero-Beaumont G. Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. Osteoarthritis Cartilage 2004, 12:878-886. 10.1016/j.joca.2004.07.007, 15501403.
36. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971, 53:523-537.
37. Palmer AW, Guldberg RE, Levenston ME. Analysis of cartilage matrix fixed charge density and three-dimensional morphology via contrast-enhanced microcomputed tomography. Proc Natl Acad Sci U S A 2006, 103:19255-19260. 10.1073/pnas.0606406103, 1748213, 17158799.
38. Xie L, Lin AS, Levenston ME, Guldberg RE. Quantitative assessment of articular cartilage morphology via EPIC-microCT. Osteoarthritis Cartilage 2009, 17:313-320. 10.1016/j.joca.2008.07.015, 2683349, 18789727.
39. Yoo WJ, Cheon JE, Lee HR, Cho TJ, Choi IH. Physeal growth arrest by excessive compression: histological, biochemical, and micro-CT observations in rabbits. Clin Orthop Surg 2011, 3:309-314. 10.4055/cios.2011.3.4.309, 3232359, 22162794.
40. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998, 6:427-434. 10.1053/joca.1998.0146, 10343776.
41. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCL reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000, 8:258-265. 10.1053/joca.1999.0299, 10903879.
42. Gouze JN, Bordji K, Gulbertis S, Terlain B, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M. Interleukin 1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effcts in rat chondrocytes. Arthritis Rheum 2001, 44:351-360. 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.0.CO;2-M, 11229466.
43. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522. 10.1001/archinte.163.13.1514, 12860572.
44. Naito K, Watari T, Furuhata A, Yomogida S, Sakamoto K, Kurosawa H, Kaneko K, Nagaoka I. Evaluation of yhe effect of glucosamine on an experimental rat osteoarthritis model. Life Sci 2010, 86:538-543. 10.1016/j.lfs.2010.02.015, 20188111.
45. Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop 2000, 381:229-240.
46. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulfate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002, 41:279-284. 10.1093/rheumatology/41.3.279, 11934964.
47. Dedrick DK, Goldstein SA, Brandt KD, O'Connor BL, Goulet RW, Albrecht M. A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum 1993, 36:1460-1467. 10.1002/art.1780361019, 8216405.
48. Kannus P, Sievanen H, Jarvinen M, Heinonen A, Oja P, Vueori I. A cruciate ligament injury produces considerable, permanent osteoporosis in the affected knee. J Bone Miner Res 1992, 7:1429-1434.
49. Karvonen RL, Miller PR, Nelson DA, Granda JL, Fernández-Madrid R. Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 1998, 25:2187-2194.
50. MacNeil JA, Doshack MR, Zernicke RF, Boyd SK. Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. Clinical Biomechanics 2008, 23:365-371. 10.1016/j.clinbiomech.2007.10.015, 18078697.
51. Zhang L, Hu H, Tiean F, Song H, Zhang Y. Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin Exp Med 2011, doi:10.1007/s10238-011-0131-z.
52. Myers SL, Brandt KD, Burr DB, O'Connor BL, Albretch M. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol 1999, 26:2645-2653.
53. Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, McNair K, Kesingland A, Green J, Chan O, Fox AJ, Urban LA. Disease modifying and antinociceptive effects of the bisphosphonate zoledronic acid in a model of bone cancer pain. Pain 2002, 100:219-229. 10.1016/S0304-3959(02)00040-4, 12467993.
54. Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronic acid in a rabbit model of inflammatory arthritis. J Rheumatol 1999, 26:1972-1982.